MedTechInvestment
A listed University of Leeds spinout in danger of going insolvent has secured $500,000 in emergency funding to help it to remain afloat.
Tissue Regenix Group appointed a new leadership team in October following the discovery of errors in previously reported revenues.
Trading in its shares on London’s AIM market were also suspended at 7.23p as it restated its 2024 revenue figures.
The firm, a regenerative medical devices company, reported a $1 million loss for last year after previously reporting a $1.9m profit after rectifying “financial inaccuracies” in its inventory and cost of sales. Its half-year 2025 results showed an EBITDA loss of $2.3m.
Chief executive Daniel Lee stepped down with immediate effect,…